Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART-P: Lenalidomide Combo in mCRPC
NCT00942578Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 3 weeks and Dose-Limiting Toxicities at 28 days. Started Jul 2009; status: completed.
02
Drugs
lenalidomide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00942578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942578.